{"downloaded": true, "htmlmade": false, "id": "37455827", "source": "MED", "pmid": "37455827", "pmcid": "PMC10344901", "fullTextIdList": {"fullTextId": "PMC10344901"}, "doi": "10.37349/etat.2023.00140", "title": "Capitalizing glycomic changes for improved biomarker-based cancer diagnostics.", "authorString": "Silva MLS.", "authorList": {"author": {"fullName": "Silva MLS", "firstName": "Maria Lu\u00edsa S", "lastName": "Silva", "initials": "MLS", "authorId": {"@type": "ORCID", "#text": "0000-0002-1170-3962"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Unidade de Aprendizagem ao Longo da Vida, Universidade Aberta, 1269-001 Lisboa, Portugal."}}}}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-1170-3962"}}, "dataLinksTagsList": {"dataLinkstag": "altmetrics"}, "journalInfo": {"issue": "3", "volume": "4", "journalIssueId": "3604292", "dateOfPublication": "2023", "monthOfPublication": "0", "yearOfPublication": "2023", "printPublicationDate": "2023-01-01", "journal": {"title": "Exploration of targeted anti-tumor therapy", "ISOAbbreviation": "Explor Target Antitumor Ther", "medlineAbbreviation": "Explor Target Antitumor Ther", "NLMid": "101770662", "ISSN": "2692-3114", "ESSN": "2692-3114"}}, "pubYear": "2023", "pageInfo": "366-395", "abstractText": "Cancer serum biomarkers are valuable or even indispensable for cancer diagnostics and/or monitoring and, currently, many cancer serum markers are routinely used in the clinic. Most of those markers are glycoproteins, carrying cancer-specific glycan structures that can provide extra-information for cancer monitoring. Nonetheless, in the majority of cases, this differential feature is not exploited and the corresponding analytical assays detect only the protein amount, disregarding the analysis of the aberrant glycoform. Two exceptions to this trend are the biomarkers \u03b1-fetoprotein (AFP) and cancer antigen 19-9 (CA19-9), which are clinically monitored for their cancer-related glycan changes, and only the AFP assay includes quantification of both the protein amount and the altered glycoform. This narrative review demonstrates, through several examples, the advantages of the combined quantification of protein cancer biomarkers and the respective glycoform analysis, which enable to yield the maximum information and overcome the weaknesses of each individual analysis. This strategy allows to achieve higher sensitivity and specificity in the detection of cancer, enhancing the diagnostic power of biomarker-based cancer detection tests.", "affiliation": "Unidade de Aprendizagem ao Longo da Vida, Universidade Aberta, 1269-001 Lisboa, Portugal.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["review-article", "Review", "Journal Article"]}, "keywordList": {"keyword": ["Cancer", "Sensitivity", "Specificity", "Biomarkers", "assays", "Aberrant Glycosylation"]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.37349/etat.2023.00140"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC10344901"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC10344901?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "0", "hasData": "N", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "hasEvaluations": "N", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCreation": "2023-07-17", "firstIndexDate": "2023-07-17", "fullTextReceivedDate": "2023-08-19", "dateOfRevision": "2023-07-18", "electronicPublicationDate": "2023-06-28", "firstPublicationDate": "2023-06-28"}